Compare AOSL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | VRDN |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2007 | 2014 |
| Metric | AOSL | VRDN |
|---|---|---|
| Price | $45.33 | $17.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $24.00 | ★ $35.46 |
| AVG Volume (30 Days) | 1.0M | ★ 3.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,291,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | $6.41 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.01 | $13.18 |
| 52 Week High | $51.35 | $34.29 |
| Indicator | AOSL | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 53.55 |
| Support Level | $19.24 | $15.65 |
| Resistance Level | $47.97 | $17.90 |
| Average True Range (ATR) | 3.69 | 0.82 |
| MACD | 0.33 | 0.24 |
| Stochastic Oscillator | 61.83 | 72.35 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.